Key result
In an exploratory study of 20 patients with HOCM, septal myectomy demonstrated a short-term hemodynamic advantage over mavacamten at 30 weeks, likely influenced by concomitant mitral valve procedures.
Why the study?
Does mavacamten compared to septal myectomy improve hemodynamic flow parameters in patients with HOCM?
Does mavacamten compared to septal myectomy improve hemodynamic flow parameters in patients with HOCM?
This response highlights that while septal myectomy with structural correction provides immediate short-term hemodynamic advantages over mavacamten in HOCM, larger prospective studies are needed to compare their long-term efficacy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) conducted a letter in Hypertrophic obstructive cardiomyopathy (HOCM) (n=20). Mavacamten vs. Septal myectomy was evaluated. In an exploratory study of 20 patients with HOCM, septal myectomy demonstrated a short-term hemodynamic advantage over mavacamten at 30 weeks, likely influenced by concomitant mitral valve procedures.
Synapse has enriched 5 related papers. Consider them for comparative context: